Skip to content
OpenCapital
Get started

Monopar Therapeutics MNPR R&D

R&D at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.65B+17.4%
Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$163M+14.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$187M+12.7%
Prime Medicine logo
Prime MedicinePRME
$34.11M-15.9%
Wave Life Sciences logo
Wave Life SciencesWVE
$47.44M+16.8%

Other financials

Income statement

See full
Revenue-—
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19—

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0×0.0×
Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's R&D?
Monopar Therapeutics (MNPR) reported R&D of $3.49M in Q1 2026.
How has Monopar Therapeutics's R&D changed year-over-year?
Monopar Therapeutics's R&D increased by 112.2% year-over-year, from $1.64M to $3.49M.
What is the long-term trend for Monopar Therapeutics's R&D?
Over 4 years (2021 to 2025), Monopar Therapeutics's R&D has grown at a 11.1% compound annual growth rate (CAGR), from $6.49M to $9.9M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.